NS5A RESISTANCE LEADING TO FAILURE OF 24-WEEK THERAPY WITH SOFOSBUVIR/LEDIPASVIR AND RIBAVIRIN FOR THE TREATMENT OF HEPATITIS C GENOTYPE 1A INFECTION IN A HIV-1 CO-INFECTED PATIENT

Abstract Herein we report a previously undescribed case of treatment-emergent non-structural protein 5A (NS5A) resistance mutations, Q30H and Y93C, leading to a failure of 24-week course of sofosbuvir/ledipasvir + ribavirin therapy for the treatment of hepatitis C virus (HCV) genotype 1a in interfer...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical virology 2016-09, Vol.82, p.66-69
Main Authors: Sevastianova, Ksenia, Dean, Jonathan, Bannan, Ciaran, Coghlan, Miriam, Farrell, Gillian, Murray, Catherine, De Gascun, Cillian F, Bergin, Colm
Format: Article
Language:English
Subjects:
Allergy and Immunology
Antiviral Agents - therapeutic use
Benzimidazoles - therapeutic use
Direct-acting antivirals
Drug Resistance, Viral
Drug Therapy, Combination
Fluorenes - therapeutic use
Genotype
HCV genotype 1a
Hepacivirus - classification
Hepacivirus - genetics
Hepacivirus - isolation & purification
Hepatitis C, Chronic - complications
Hepatitis C, Chronic - drug therapy
HIV
HIV Infections - complications
HIV-1 - isolation & purification
Humans
Infectious Disease
Ledipasvir
Liver Cirrhosis - drug therapy
Liver Cirrhosis - virology
Male
Middle Aged
Mutation, Missense
Resistance
Ribavirin - therapeutic use
Sofosbuvir
Sofosbuvir - therapeutic use
Treatment Failure
Viral Nonstructural Proteins - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Herein we report a previously undescribed case of treatment-emergent non-structural protein 5A (NS5A) resistance mutations, Q30H and Y93C, leading to a failure of 24-week course of sofosbuvir/ledipasvir + ribavirin therapy for the treatment of hepatitis C virus (HCV) genotype 1a in interferon-experienced, human immunodeficiency virus type 1 (HIV-1) co-infected patient with cirrhosis.
ISSN:1386-6532
1873-5967
DOI:10.1016/j.jcv.2016.06.012